Gossamer Bio Announces Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update
Gossamer Bio, Inc. (GOSS)
Last gossamer bio, inc. earnings: 3/24 07:00 am
Check Earnings Report
Company Research
Source: Business Wire
- PROSERA Phase 3 in PAH on Track for Topline Data Readout in Fourth Quarter of 2025 -- Registrational Phase 3 in PH-ILD Expected to Commence in Second Half of 2025 -- Seralutinib Receives Orphan Drug Designation for PAH in Japan -- Cash, cash equivalents and marketable securities totaled $295 million at year-end 2024 - SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced its financial results for the fourth quarter and year ended December 31, 2024, and provided a business update.“As we close the book on 2024 and embrace the promise of 2025, I am both humbled and energized by the remarkable progress that Gossamer has made in its mission to improve the lives of pulmonary hypertension patients,” said Faheem Hasn
Show less
Read more
Impact Snapshot
Event Time:
GOSS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GOSS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GOSS alerts
High impacting Gossamer Bio, Inc. news events
Weekly update
A roundup of the hottest topics
GOSS
News
- Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Business Wire
- How Recent Developments Are Shaping the Gossamer Bio Investment Story [Yahoo! Finance]Yahoo! Finance
- Gossamer Bio to Participate in Upcoming Investor ConferencesBusiness Wire
- Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Business Wire
- Gossamer Bio to Participate in Upcoming Investor ConferencesBusiness Wire
GOSS
Earnings
- 11/5/25 - Miss
GOSS
Sec Filings
- 11/5/25 - Form 8-K
- 11/5/25 - Form 10-Q
- 10/2/25 - Form 4
- GOSS's page on the SEC website